| |
All patients
|
|---|
|
(n = 50)
|
Missing
|
|---|
|
Sex
|
|
Male (%)
|
34 (68.0)
| |
|
Female (%)
|
16 (32.0)
|
|
Age (y)
|
|
Median (range)
|
69 (41–83)
| |
|
ECOG PS
|
|
0 (%)
|
13 (26.0)
|
2 (4.0)
|
|
1 (%)
|
31 (62.0)
|
|
≥ 2 (%)
|
4 (8.0)
|
|
Prior surgical resection
|
25 (50.0)
| |
|
Tumor location
|
|
Head (%)
|
24 (48.0)
| |
|
Body-Tail (%)
|
26 (52.0)
|
|
Tumor size (cm)
|
|
Median (range)
|
4.5 (2.0–18.0)
|
1 (2.0)
|
|
Extent of disease
|
|
Locally advanced (%)
|
6 (12.0)
| |
|
Metastatic (%)
|
44 (88.0)
|
|
Measurable metastatic sites
|
|
Liver (%)
|
26 (52.0)
| |
|
Lymph node (%)
|
20 (40.0)
|
|
Lung (%)
|
4 (8.0)
|
|
Peritoneal (%)
|
12 (24.0)
|
|
LDH, U/L
|
|
Median (range)
|
205 (128–909)
|
2 (4.0)
|
|
CRP, mg/L
|
|
Median (range)
|
13 (0–178)
|
2 (4.0)
|
|
CEA, ng/mL
|
|
Median (range)
|
3.0 (0.7–64.1)
|
1 (2.0)
|
|
CA19–9, U/mL
|
|
Median (range)
|
35.7 (1.0–43,645)
|
1 (2.0)
|
|
Histological subtype
|
|
Anaplastic type (%)
|
16 (32.0)
| |
|
Sarcomatoid type (%)
|
4 (8.0)
|
|
Undifferentiated carcinoma with OGCs (%)
|
11 (22.0)
|
|
NOS (%)
|
19 (38.0)
|
- ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehydrogenase, CRP C-reactive protein, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9, OGCs osteoclast-like giant cells, NOS not otherwise specified
